Cholalic Acid
Smith-Lemli-Opitz Syndrome
Floatz Rating
CCC49/100
Confidence
Indicative
Sponsor
University of Nebraska
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
34Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03720990CT.gov Smith-Lemli-Opitz Syndrome and Cholic Acid | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Smith-Lemli-Opitz Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cholalic Acid (this asset) | University of Nebraska | P1/2 | CCC · 49 |
| Cholesterol Suspension | University of Colorado, Denver | P2 | B |
| Simvastatin | Oregon Health and Science University | P2 | CCC |
| Lovastatin | Northwestern University | P2 | CC |
| Crh | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Unk | D |
Other indications for Cholalic Acid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Zellweger Spectrum Disorders | — | P3 | CCC · 54 |
| Adrenoleukodystrophy | — | P3 | CCC · 54 |
| Peroxisome Biogenesis Disorder | — | P3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cholalic Acid in Smith-Lemli-Opitz Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cholalic-acid-smith-lemli-opitz-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →